◎ Sugi Atlas

Atlas / Drug / Bortezomib

Bortezomib

drug
On this page

Also known as Bortezomib hydrateLDP-341NSC-681239PS-341Dipeptidyl boronic acid derivativePeptidyl boronic acid derivativeSID518755SID124950705SID144206183SID144206225SID170465087Velcade

Summary

Bortezomib (CHEMBL325041) is an approved small-molecule antineoplastic agent (ATC L01XG01) targeting PSMB5; indicated across 107 conditions including neoplasm and leukemia; with CIViC clinical evidence for 3 variant-indication associations (e.g. CCND1 Overexpression in multiple myeloma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XG01
  • Targets: 1 (PSMB5)
  • Indications: 107 conditions
  • Clinical trials: 866
  • Precision-oncology evidence (CIViC): 3 variant–indication associations
  • Chemistry: 384.2 Da · C19H25BN4O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL325041
NameBortezomib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID387447
ChEBICHEBI:52717
ATCL01XG01
Molecular formulaC19H25BN4O4
Molecular weight384.2
InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N

SMILES: B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

IUPAC name: [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid

ChEBI definition: L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at Nα by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome.

Pharmacological roles (ChEBI): antineoplastic agent, proteasome inhibitor, protease inhibitor, antiprotozoal drug.

Also known as: Bortezomib, Bortezomib hydrate, LDP-341, NSC-681239, PS-341, Dipeptidyl boronic acid derivative, Peptidyl boronic acid derivative, bortezomib, SID518755, BORTEZOMIB, SID124950705, SID144206183

Parent form; salt/anhydrous children: CHEMBL5315122

Patent coverage: 3,917 distinct patent families (13,120 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 12,876 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PSMB5proteasome 20S subunit beta 5Inhibition7.795% (common-essential)P28074
Plasmodium falciparum proteasome subunit beta type-57.51

Broader ChEMBL bioactivity targets: 41 (assay-derived). Sample: Histone deacetylase 3, Protein deacetylase HDAC6, ATP-dependent Clp protease proteolytic subunit, Histone deacetylase 2, Proteasome subunit beta type-8, Proteasome subunit beta type-9, Proteasome subunit beta type-6, Prothrombin, Carbonic anhydrase 2, Nuclear factor NF-kappa-B complex.

Bioactivity

ChEMBL activities: 122 potent at pChembl ≥ 5 of 126 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PSMB59.3IC500.5nMCHEMBL_ACT_18537720
PSMB59.26Ki0.55nMCHEMBL_ACT_14528999
PSMB59.22Ki0.6nMCHEMBL_ACT_13322909
PSMB119.22Ki0.6nMCHEMBL_ACT_29064079
PSMB119.22Ki0.6nMCHEMBL_ACT_29278081
PSMB88.89IC501.3nMCHEMBL_ACT_24866178
PSMB58.72IC501.9nMCHEMBL_ACT_16532743
PSMB58.72IC501.9nMCHEMBL_ACT_16548365
PSMB58.7IC502nMCHEMBL_ACT_14526779
PSMB88.7IC502nMCHEMBL_ACT_22456283
PSMB58.62IC502.4nMCHEMBL_ACT_24972784
PSMB118.62IC502.4nMCHEMBL_ACT_25524559
PSMB118.59IC502.56nMCHEMBL_ACT_14550610
PSMB58.55IC502.8nMCHEMBL_ACT_24746484
PSMB58.55IC502.82nMCHEMBL_ACT_24746486
PSMB98.54IC502.9nMCHEMBL_ACT_24866168
PSMB98.52IC503nMCHEMBL_ACT_19300208
PSMB118.52IC503nMCHEMBL_ACT_25918282
PSMB58.52IC503nMCHEMBL_ACT_25999750
PSMB58.49IC503.2nMCHEMBL_ACT_24866230
PSMB88.48IC503.3nMCHEMBL_ACT_19258360
PSMB58.47Ki3.4nMCHEMBL_ACT_25995183
PSMB58.41IC503.9nMCHEMBL_ACT_14526811
PSMB58.4IC504nMCHEMBL_ACT_18195674
PSMB58.4IC504nMCHEMBL_ACT_18249143
PSMB58.4IC504nMCHEMBL_ACT_18259017
PSMB88.4IC504nMCHEMBL_ACT_19300202
PSMB88.4IC504nMCHEMBL_ACT_25999712
PSMB98.4IC504nMCHEMBL_ACT_25999731
PSMB58.35IC504.5nMCHEMBL_ACT_12699996

Target pathways

Aggregated over 1 target gene(s): PSMB5.

Top Reactome pathways

68 total, by targets touching each:

PathwayTargetsGenes
Activation of NF-kappaB in B cells1PSMB5
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha1PSMB5
ER-Phagosome pathway1PSMB5
Cross-presentation of soluble exogenous antigens (endosomes)1PSMB5
Autodegradation of Cdh1 by Cdh1:APC/C1PSMB5
SCF-beta-TrCP mediated degradation of Emi11PSMB5
APC/C:Cdc20 mediated degradation of Securin1PSMB5
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G11PSMB5
Cdc20:Phospho-APC/C mediated degradation of Cyclin A1PSMB5
Vpu mediated degradation of CD41PSMB5
Vif-mediated degradation of APOBEC3G1PSMB5
SCF(Skp2)-mediated degradation of p27/p211PSMB5
Degradation of beta-catenin by the destruction complex1PSMB5
Downstream TCR signaling1PSMB5
Regulation of activated PAK-2p34 by proteasome mediated degradation1PSMB5
Separation of Sister Chromatids1PSMB5
FCERI mediated NF-kB activation1PSMB5
Autodegradation of the E3 ubiquitin ligase COP11PSMB5
Regulation of ornithine decarboxylase (ODC)1PSMB5
ABC-family protein mediated transport1PSMB5
AUF1 (hnRNP D0) binds and destabilizes mRNA1PSMB5
Asymmetric localization of PCP proteins1PSMB5
Degradation of AXIN1PSMB5
Degradation of DVL1PSMB5
Hedgehog ligand biogenesis1PSMB5
Hh mutants are degraded by ERAD1PSMB5
Dectin-1 mediated noncanonical NF-kB signaling1PSMB5
CLEC7A (Dectin-1) signaling1PSMB5
Degradation of GLI1 by the proteasome1PSMB5
Degradation of GLI2 by the proteasome1PSMB5

Dominant GO biological processes

GO termTargets
proteolysis1
response to oxidative stress1
proteasomal ubiquitin-independent protein catabolic process1
proteasome-mediated ubiquitin-dependent protein catabolic process1
proteasome assembly1
obsolete proteolysis involved in protein catabolic process1

Indications & clinical

Indications

107 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
leukemia3MONDO:0005059EFO:0000565
plasma cell myeloma3MONDO:0009693EFO:0001378
lymphoma3MONDO:0005062EFO:0000574
acute myeloid leukemia3MONDO:0018874EFO:0000222
mantle cell lymphoma3MONDO:0018876EFO:1001469
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
chronic kidney disease3MONDO:0005300EFO:0003884
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
plasmacytoma3MONDO:0005615EFO:0006738
autoimmune thrombocytopenic purpura3MONDO:0008558EFO:0007160
myeloid sarcoma3MONDO:0006861EFO:1001052
amyloidosis3MONDO:0019065EFO:1001875
intrahepatic cholangiocarcinoma3MONDO:0003210EFO:1001961
Waldenstrom macroglobulinemia3MONDO:0100280EFO:0009441
hereditary amyloidosis3MONDO:0018634MONDO:0019438
graft versus host disease2MONDO:0013730EFO:0004599
melanoma2MONDO:0005105EFO:0000756
acute promyelocytic leukemia2MONDO:0012883EFO:0000224
myelodysplastic syndrome2MONDO:0018881EFO:0000198
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
mesothelioma2MONDO:0005065EFO:0000588
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
neuromyelitis optica2MONDO:0019100EFO:0004256
bronchiolitis obliterans syndrome2MONDO:0015265EFO:0007183
B-cell acute lymphoblastic leukemia2MONDO:0004947EFO:0000094
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
Hodgkins lymphoma2MONDO:0004952EFO:0000183
MALT lymphoma2MONDO:0007650EFO:0000191
T-cell acute lymphoblastic leukemia2MONDO:0004963EFO:0000209
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
adenoid cystic carcinoma2MONDO:0004971EFO:0000231
chronic myeloid leukemia2MONDO:0011996EFO:0000339
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501
glioblastoma2MONDO:0018177EFO:0000519
immune system disorder2MONDO:0005046EFO:0000540
thyroid gland papillary carcinoma2MONDO:0005075EFO:0000641
sarcoma2MONDO:0005089EFO:0000691
lymphoid neoplasm2MONDO:0005157EFO:0001642
prostate carcinoma2MONDO:0005159EFO:0001663
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
plasma cell leukemia2MONDO:0018689EFO:0006475
head and neck cancer2MONDO:0005627EFO:0006859
gliosarcoma2MONDO:0016681EFO:1001465
lung adenocarcinoma2MONDO:0005061EFO:0000571
central nervous system neoplasm2MONDO:0006130EFO:1000158
soft tissue sarcoma2MONDO:0018078EFO:1001968
gastric neoplasm2MONDO:0021085MONDO:0001056
kidney cancer2MONDO:0002367MONDO:0002367
breast neoplasm2MONDO:0021100MONDO:0007254
ovarian cancer2MONDO:0008170MONDO:0008170
ureter cancer2MONDO:0008627MONDO:0008627
lung neoplasm2MONDO:0021117MONDO:0008903
Castleman disease2MONDO:0015564MONDO:0015564
follicular lymphoma2MONDO:0018906MONDO:0018906
acute biphenotypic leukemia2MONDO:0020322MONDO:0019460
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
breast carcinoma2MONDO:0004989EFO:0000305
pure red-cell aplasia2MONDO:0001705MONDO:0001705
lymphoproliferative syndrome2MONDO:0016537MONDO:0016537
autoimmune hemolytic anemia2MONDO:0020108MONDO:0018922
plasma cell neoplasm2MONDO:0004959EFO:0000200
paraganglioma2MONDO:0000448EFO:1000453
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
colorectal neoplasm2MONDO:0005335MONDO:0005575
autoimmune disorder of the nervous system2MONDO:0002977MONDO:0020640
neuroblastoma1MONDO:0005072EFO:0000621
renal cell carcinoma1MONDO:0005086EFO:0000681
squamous cell carcinoma1MONDO:0005096EFO:0000707
anaplastic astrocytoma1MONDO:0016684EFO:0002499
anaplastic oligodendroglioma1MONDO:0016696EFO:0002501
smoldering plasma cell myeloma1MONDO:0005235EFO:0003073
myelodysplastic syndrome with excess blasts1MONDO:0019454EFO:0003811
angioimmunoblastic T-cell lymphoma1MONDO:0004977EFO:0000255
Burkitt lymphoma1MONDO:0007243EFO:0000309
anaplastic large cell lymphoma1MONDO:0020325EFO:0003032
Sezary syndrome1MONDO:0017844EFO:1000785
mycosis fungoides1MONDO:0009691EFO:1001051
uremia1MONDO:0007008EFO:1001226
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
lymphoid leukemia1MONDO:0005402EFO:0004289
muscular dystrophy1MONDO:0020121MONDO:0016145
myeloproliferative neoplasm0MONDO:0020076EFO:0002428

21 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 866.

Phase distribution

PhaseTrials
PHASE2409
PHASE1169
PHASE3108
PHASE1/PHASE2103
Not specified40
PHASE422
PHASE2/PHASE38
EARLY_PHASE17

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03829371PHASE4ACTIVE_NOT_RECRUITINGSTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03844360PHASE4RECRUITINGDose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
NCT07025005PHASE4RECRUITINGFenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
NCT07334535PHASE4NOT_YET_RECRUITINGIsa-VRD in TIE HRMM
NCT00257114PHASE4COMPLETEDEvaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00652041PHASE4COMPLETEDBortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00782821PHASE4COMPLETEDRandomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
NCT00908583PHASE4COMPLETEDDesensitization in Kidney Transplantation
NCT01103778PHASE4COMPLETEDPilot Study of Velcade® in IgA Nephropathy
NCT01169857PHASE4WITHDRAWNVelcade for Proliferative Lupus Nephritis
NCT01249690PHASE4UNKNOWNEfficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01842074PHASE4UNKNOWNDesensitization With Bortezomib Before a Living Kidney Donation
NCT02268890PHASE4COMPLETEDA Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02525172PHASE4UNKNOWNImmune Modulation Therapy for Pompe Disease
NCT02559154PHASE4UNKNOWNModified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02773550PHASE4TERMINATEDTreatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02844322PHASE4COMPLETEDThe Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
NCT03416374PHASE4COMPLETEDA Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
NCT04348006PHASE4WITHDRAWNAssessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
NCT05135442PHASE4UNKNOWNEfficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP
NCT05137860PHASE4UNKNOWNEfficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
NCT06015750PHASE4WITHDRAWNMitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
NCT00572169PHASE3ACTIVE_NOT_RECRUITINGUARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
NCT00644228PHASE3ACTIVE_NOT_RECRUITINGLenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT01208662PHASE3ACTIVE_NOT_RECRUITINGRandomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01863550PHASE3ACTIVE_NOT_RECRUITINGBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT02112916PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT03117751PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTotal Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03319667PHASE3ACTIVE_NOT_RECRUITINGA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT03617731PHASE3ACTIVE_NOT_RECRUITINGTrial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03643276PHASE3RECRUITINGTreatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03651128PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03652064PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT03710603PHASE3ACTIVE_NOT_RECRUITINGDaratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
NCT03729804PHASE3ACTIVE_NOT_RECRUITINGCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03742297PHASE3ACTIVE_NOT_RECRUITINGTreatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
NCT04181827PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04246047PHASE3ACTIVE_NOT_RECRUITINGEvaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04484623PHASE3ACTIVE_NOT_RECRUITINGBelantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04566328PHASE3RECRUITINGTesting the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Clinical evidence (CIViC)

Variant × indication × effect (3 predictive associations from 3 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
CCND1 OverexpressionMultiple MyelomaSensitivity/ResponseBortezomibCIViC CEID7788
TP53 Y220CBreast CancerSensitivity/ResponseBortezomibCIViC CEID6172
GATA2 EXPRESSIONLung AdenocarcinomaSensitivity/ResponseBortezomib + FasudilCIViC DEID301

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

12 molecules share ≥1 primary target. Top 12 by shared-target count:

MoleculeSourceStatusShared targets
CARFILZOMIBChEMBL + PubChemPhase 4 (approved)PSMB5
IXAZOMIBChEMBLPhase 4 (approved)PSMB5
VINBLASTINEChEMBLPhase 4 (approved)PSMB5
CURCUMINChEMBLPhase 3PSMB5
EPIGALOCATECHIN GALLATEChEMBLPhase 3PSMB5
MARIZOMIBChEMBLPhase 3PSMB5
QUERCETINChEMBLPhase 3PSMB5
DELANZOMIBChEMBLPhase 2PSMB5
GENISTEINChEMBLPhase 2PSMB5
LUTEOLINChEMBLPhase 2PSMB5
OPROZOMIBChEMBLPhase 2PSMB5
ZETOMIPZOMIBChEMBLPhase 2PSMB5

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot